Systems Oncology is developing a new class of multimodal RNA therapeutics that can simultaneously silence numerous disease targets with a single RNA molecule to improve outcomes and combat emerging drug resistance. Our Arromer platform is used to digitally engineer and rapidly produce self-delivering therapeutics which target specific tissues with unprecedented precision and accuracy. We are focused on building a pipeline of products in oncology, yet our multimodal RNA platform can be harnessed to transform outcomes for any complex polygenic disease.